Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Alcubierre N, Navarrete-Muñoz EM, Rubinat E, Falguera M, Valls J, Traveset A, Vilanova MB, Marsal JR, Hernandez M, Granado-Casas M, Martinez-Gonzalez D, Jurjo C, Franch-Nadal J, Vioque J, Mauricio D. Association of low oleic intake acid with diabetic retinopathy in type 2 diabetic patients: a case-control study. Nutr Metab (Lond). 2016 Jun 4;13(40). doi: 10.1186/s12986-016-0099-5
Goyal RK, Wheeler SB, Kohler RE, Lich KH, Lin CC, Reeder-Hayes K, Meyer AM, Mayer DK. Health care utilization from chemotherapy-related adverse events among low-income breast cancer patients: effect of enrollment in a medical home program. N C Med J. 2014 Jul;75(4):231-8.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Ferris M, Patel UD, Massengill S, Gipson D, Conley W, Layton JB, Nagaraj S, Primack W. Pediatric chronic kidney disease in North Carolina. N C Med J. 2008 May;69(3):208-14.
Westfall PH, Prillaman B, Ho SY. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials. J Biopharm Stat. 2001;11(3):125-38. doi: 10.1081/BIP-100107653